LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

Paul Nathan, Dirk Schadendorf, Pier Francesco Ferrucci et al.|Annals of Oncology|2020

Cited by 68